Introducing OptimersTM

3rd October 2018


Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks

Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the shortest time possible. We are now including as standard our proprietary automated Minimal Aptamer Fragment Identification (MAFI) process for the development of kinetically optimised aptamers in the same delivery time as our previous approach. These improved aptamers will be differentiated from the standard library aptamers as OptimersTM.

OptimersTM can have multiple advantages, when compared to their precursor aptamer sequences, making kinetic optimisation an essential step in the development of the highest quality reagents against cellular, protein or small molecular targets.

Improved Development Timelines


  • Fully optimised reagents without additional development time
  • Improved Binding Kinetics and Specificity after optimisation.
  • Reduced production costs, minimisation reduces the cost of production by over 50%.

Figure 1 – Small molecule binding OptimerTM
Comparison of Biolayer Interferometry response curves demonstrate that the OptimerTM (green) has improved binding parameters, compared to those of the parent aptamer (red). The naïve library (blue) shows no response to the small molecule target.  A 58% reduction in size was achievable from 33kDa to 13.8kDa, whilst improving binding kinetics.

Figure 2 – Protein binding OptimerTM in ELISA-like assay
Fluorescently labelled Optimer (red) and parent aptamer (blue) both show a concentration dependent response when used in an ELISA-like assay. The data shows that OptimersTM produce a noticeably stronger signal than the full length aptamer leading to an improved limit of detection.

Figure 3 – Protein binding OptimerTM with improved binding and elution
In this example the immobilised Naïve library (blue) shows no binding to the protein sample. The immobilised parent aptamer (red) shows strong binding to the target with little material lost during the wash (KD~410nM). Rapid elution is evident upon changing the buffer. The minimal fragments (green) show a range of properties; some lose this binding property, while others have slightly improved binding and elution profiles. The best performing ‘Optimer’ has KD ~200nM. The ‘Mfold’ predicted secondary structures for the parent aptamer (bottom) and the aptamer fragments which retained their binding properties (centre) and the OptimerTM (top).


If you are interested in reducing future assay costs, improving performance of your assay, downstream processing or therapeutic activity, then OptimerTM development would be the better solution.

If you are facing challenges that OptimersTM could address and are attracted by the benefits they offer, contact our team at where they will be available to answer any queries you have.